Le Lézard
Classified in: Health, Business
Subjects: LIC, TRI

Beacon Discovery announces multi-year GPCR-focused drug discovery collaboration with Janssen Pharmaceuticals



SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- Beacon Discovery, a leading drug discovery company focused on G-Protein Coupled Receptor (GPCR) research, today announced it has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the terms of the agreement, Beacon and Janssen will focus on the discovery and development of small molecule compounds for multiple undisclosed GPCR targets for the treatment of metabolic diseases.

Through the collaboration, the companies will conduct research to identify drug candidates for the treatment of obesity and other metabolic diseases where significant unmet medical need exists.  "We are delighted to be part of this strategic discovery collaboration which realizes our vision to combine our GPCR drug discovery expertise with the therapeutic area strengths and development capabilities of Janssen and our other corporate partners," said Sunny Al-Shamma, Beacon's CEO.

The agreement grants Janssen an option to exercise and obtain worldwide rights to develop, manufacture and commercialize products resulting from the collaboration. In exchange, Beacon will receive an upfront payment, and if the option is exercised, milestones and royalties on future sales of such products.

About Beacon

Founded in 2016 and headquartered in San Diego, California, Beacon Discovery is a privately held company that is a world leader in all facets of GPCR-focused drug discovery.  Beacon's mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.  Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.  In addition to the external collaborations, Beacon also has a number of internal programs focused on therapeutically important targets to address unmet medical needs.

About GPCRs

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Close to 30% of marketed drugs target this receptor family. GPCR research has expanded in recent years from traditional orthosteric receptor-ligand interactions to encompass new approaches based on signaling via beta-arrestin, biased ligands, allosteric ligands, and persistent signaling. In addition, the revolution in GPCR structural biology has enabled significant advances in both biophysical methods and computational modeling of receptors which can aid in the design of new molecules to target these receptors.

For more information:

Visit www.beacondiscovery.com

 

SOURCE Beacon Discovery


These press releases may also interest you

at 08:19
Warriors and their families enjoyed the beautiful spring weather as they learned about equine therapy during a day on the farm with Wounded Warrior Project® (WWP). "I signed up for this event primarily because my son...

at 03:00
HOUSTON, Aug. 19, 2018 /PRNewswire-PRWeb/ -- DermaTouch RN of Houston is excited to announce the recent launch of their Forever Young Membership Program. The Program is designed for individuals who care about their ongoing skincare needs and are...

at 03:00
SINGAPORE and Utah, Aug. 19, 2018 /PRNewswire-PRWeb/ -- MXR International Pte Ltd (MXRi), a specialist provider of AR/VR platform for education, publishing and training and Zygote Media Group, Inc., today announced the partnership to integrate...

at 00:00
Daniel Tu, former group chief innovation officer of Ping An Insurance (Group) Company of China Ltd, has joined the Ottawa-based technology group autonomous_ID as executive advisor to the chairman, Todd Gray. Mr. Tu drove...

18 aoû 2018
SANTA ROSA, Calif., Aug. 18, 2018 /PRNewswire-PRWeb/ -- On October 8 2017, Sonoma County suffered the worst wildfire in California history. The Tubbs Fire was an unprecedented natural disaster that created an unusual and extremely difficult...

18 aoû 2018
Health Canada is advising Canadians that, as a precautionary measure, Teva Canada is expanding its voluntary recall to include eight additional lots of valsartan products in Canada because they may contain an impurity, N-nitrosodimethylamine (NDMA)....




News published on 4 january 2018 at 08:00 and distributed by: